KromaTiD Joins NIST Genome Editing Consortium

KromaTiD, Inc. announced today that it has joined the National Institutes of Standards and Technology Genome Editing Consortium, a newly launched public/private partnership ( The Consortium supports the emerging gene editing market and regulatory agency needs for standardized measurements of gene edits, editing by-products and the risks of utilizing genome editing technologies in research, commercial and therapeutic products.

KromaTiD’s dGH™ is a commercial structural genomic platform uniquely capable of de novo detection of random, low frequency and complex structural variations in batches of gene edited cells. By directly reading the genomic structure of individual edited cells, dGH provides definitive, quantitative data for on- and off-target structural variation. By combining dGH with a technique such as Guide-seq (, it is now possible to measure the entire range of editing outcomes ranging from successful edits, to indels, to rearrangements of random genomic segments.

KromaTiD’s President and Chief Technology Officer, Christopher Tompkins, PhD presented the dGH platform at the recent joint FDA-NIST workshop held in Gaithersburg. dGH was developed as a sensitive method to assess structural changes to the genome arising from any source, including ionizing radiation, environmental exposures and any gene editing platform. According to Dr. Tompkins, “as a single cell, quantitative measurement of structural variation, dGH assays are ideally suited for the process control, optimization and regulatory requirements of the gene editing market”. dGH can also be used to assess pre-existing structural variation in subjects before gene editing, setting a baseline for critical studies and can provide an essential measurement of error free cells.

Through a cooperative research and development agreement, KromaTiD will transfer dGH technology to laboratories at NIST and other consortium members.